Using Whole Body MRI to Improve Cancer Detection
Whole Body MRI in Oncology
This study is testing if Whole Body MRI can help find bone and soft tissue problems in people with different types of cancer, like lymphoma and advanced prostate and breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Academic / other |
| Drugs / interventions | radiation |
| Locations | 3 sites (Bologna, BO and 2 other locations) |
| Trial ID | NCT06895291 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of Whole Body Magnetic Resonance Imaging (WB-MRI) in detecting bone and soft tissue pathology in patients with various cancers, including lymphoma and advanced prostate and breast cancer. Patients will undergo WB-MRI as part of their routine clinical care without any additional procedures. The study aims to assess the imaging technique's ability to provide high-quality morphological images and functional information about tissue cellularity. The findings could help establish WB-MRI as a standard imaging method in oncology.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with specific cancers who are eligible for WB-MRI according to clinical practice.
Not a fit: Patients with MRI-unsafe prostheses or devices, or those unable to complete the MRI, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance cancer detection and monitoring, leading to better patient outcomes.
How similar studies have performed: Previous studies have shown promising results with WB-MRI in oncology, indicating its potential as a valuable imaging technique.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above. * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged ≥ 18 years. * Life expectancy greater than 3 months. Exclusion Criteria: * Patients with MRI-unsafe prostheses and devices. * Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete.
Where this trial is running
Bologna, BO and 2 other locations
- IRCCS - Azienda Ospedaliero-Universitaria di Bologna - Policlinico di S. Orsola — Bologna, Bo, Italy (Recruiting)
- IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. — Meldola, Fc, Italy (Recruiting)
- IRCCS Istituto Europeo di Oncologia S.r.l. — Milan, Mi, Italy (Not_yet_recruiting)
Study contacts
- Principal investigator: Alice Rossi — IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
- Study coordinator: Oriana Nanni
- Email: cc.ubsc@irst.emr.it
- Phone: +390543739266
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.